Peptide-Based Cancer Vaccines: Current Clinical Progress and Combination Strategies
Comprehensive review of peptide-based therapeutic cancer vaccines covering target selection, epitope design, adjuvant optimization, clinical trial results, and combination strategies with other immunotherapies and treatments.
Quick Facts
What This Study Found
Peptide cancer vaccines targeting TAAs or TSAs via CD8+/CD4+ epitopes have achieved clinical benefits. Adjuvants and nanomaterials improve immune responses. Combination with other therapies shows superior anti-cancer efficacy. Multiple candidates in advanced clinical development.
Key Numbers
Targets: TAAs and TSAs; stimulates CD8+ and CD4+ T cells; adjuvants and nanomaterials reviewed
How They Did This
Comprehensive narrative review of peptide-based therapeutic cancer vaccine development, covering target selection, epitope design/screening, adjuvant optimization, clinical trial results, and combination therapy strategies.
Why This Research Matters
Unlike antibody immunotherapies (expensive, IV infusion), peptide vaccines are relatively cheap, easy to manufacture, and can be personalized. Understanding the current clinical landscape helps identify which approaches are most promising.
The Bigger Picture
Peptide cancer vaccines are evolving from single-antigen, single-modality approaches to multi-antigen, combination therapies. The field is maturing from "can this work?" to "how do we optimize it for each patient?"
What This Study Doesn't Tell Us
Broad review — individual clinical trial details not deeply analyzed. Response rates for peptide vaccines alone remain modest. Tumor immune escape remains a challenge. Personalized neoantigen vaccines are logistically complex.
Questions This Raises
- ?Which peptide vaccine-combination strategy shows the greatest clinical promise?
- ?Can AI-predicted neoantigens replace experimentally identified ones?
- ?Will mRNA vaccines eventually replace peptide vaccines for cancer?
Trust & Context
- Key Stat:
- Combinations are key Peptide vaccines combined with checkpoint inhibitors, chemotherapy, or radiation show superior anti-cancer efficacy — the future is combination immunotherapy
- Evidence Grade:
- Not applicable (comprehensive review). Based on published clinical trial data across multiple peptide vaccine programs.
- Study Age:
- Published 2021. Peptide cancer vaccines continue advancing with mRNA vaccines providing both competition and complementary technology.
- Original Title:
- Peptide-based therapeutic cancer vaccine: Current trends in clinical application.
- Published In:
- Cell proliferation, 54(5), e13025 (2021)
- Authors:
- Liu, Wensi, Tang, Haichao(2), Li, Luanfeng, Wang, Xiangyi, Yu, Zhaojin, Li, Jianping
- Database ID:
- RPEP-05561
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is a peptide cancer vaccine?
A peptide cancer vaccine contains short protein fragments (peptides) from tumor-specific proteins that train the immune system to recognize and attack cancer cells. Unlike preventive vaccines (like HPV), therapeutic cancer vaccines treat existing cancer.
Do peptide cancer vaccines work?
On their own, responses are often modest. But when combined with checkpoint inhibitors (like Keytruda), chemotherapy, or radiation, peptide vaccines have shown significant clinical benefits in multiple trials. The combination approach is where the field is heading.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05561APA
Liu, Wensi; Tang, Haichao; Li, Luanfeng; Wang, Xiangyi; Yu, Zhaojin; Li, Jianping. (2021). Peptide-based therapeutic cancer vaccine: Current trends in clinical application.. Cell proliferation, 54(5), e13025. https://doi.org/10.1111/cpr.13025
MLA
Liu, Wensi, et al. "Peptide-based therapeutic cancer vaccine: Current trends in clinical application.." Cell proliferation, 2021. https://doi.org/10.1111/cpr.13025
RethinkPeptides
RethinkPeptides Research Database. "Peptide-based therapeutic cancer vaccine: Current trends in ..." RPEP-05561. Retrieved from https://rethinkpeptides.com/research/liu-2021-peptidebased-therapeutic-cancer-vaccine
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.